Amneal Pharmaceuticals, Inc. (AMRX)
Healthcare
- Fundamental
- 3
- Sentiment
- 3
- Technical
- 3
Bullish pullback_to_support limit: buy 20.38 at the EMA21/SMA20 confluence (EMA21 20.38, SMA20 20.35, just above the 2026-11-09 higher low of 20.29) inside a stacked uptrend where 21.38 holds above SMA20/50/200 and MACD's line is positive; stop 19.54 (Change-A 1.0xATR floor, structure at 20.12), T1 22.06, T2 23.32, R/R 2.00. No breakout stop qualifies: a buy-stop above the settled 21.68 shelf would carry the same 20.12 structure stop for 1.58 of risk = 1.88xATR and R/R only 1.06, below the 1.5 screen.
Company overview
Amneal Pharmaceuticals, Inc. is a diversified pharmaceutical company involved in developing, manufacturing, and distributing generic and specialty medicines. It operates through three divisions: Generics, Specialty, and AvKARE, serving a wide range of therapeutic needs and markets, including government entities.
Fundamental
fairAmneal shows revenue growth and margin improvement but faces high leverage and cash conversion challenges post-acquisition.
Amneal is a leveraged, cash-generative generics and biosimilars manufacturer whose operating trajectory has improved materially while its balance sheet and cash conversion have deteriorated after the related-party Kashiv Biosciences acquisition. The FY2025 Form 10-K (filed 2026-02-27) shows revenue of $3.019B (+8.0%), gross margin of 36.9%, operating income of $394.1M (+58%), net income attributable to Amneal of $72.1M and operating cash flow of $340.0M, with an unqualified auditor opinion, no going-concern language, no material weakness and compliance with all credit-facility covenants; only $21.0M of term-loan principal came due in 2026 and no maturity falls before 2030. The Q3 2026 Form 10-Q (filed 2026-11-09) shows nine-month revenue of $2.381B (+8.0%), gross margin up to 41.5% from 37.0%, GAAP operating income up 30.1% to $367.0M and net income attributable of $98.2M, but also a 76% collapse in nine-month operating cash flow to $50.3M, a $21.7M net loss attributable in Q3 itself, and gross debt of $3.23B after the $350M incremental term loan and $180M revolver draw used to fund the $1.30B preliminary Kashiv consideration (which also issued 28.9M shares, added $963M of indefinite-lived IPR&D and $389M of contingent consideration). Management still asserts 12-month liquidity sufficiency with $157.4M of cash plus $415.2M of revolver availability, and no going-concern, covenant-breach, waiver or auditor-modification marker exists. Trajectory reconciliation: FY2025 shows improving profitability and deleveraging, whereas interim 2026 shows continued revenue and gross-margin expansion but sharply weaker operating cash flow and a Q3 attributable loss; the fresher period was weighted for distress assessment because its GAAP operating income is also rising and the cash shortfall is largely traceable to disclosed discrete items (about $35.9M of opioid settlement payments, $38.8M of TRA payments, roughly $35M of acquisition and integration costs and a deliberate inventory build), so the deterioration reflects capital deployment and working capital rather than a broken operating model. Non-recurring/non-cash distortion: FY2025's swing to GAAP profitability is flattered by the absence of FY2024's $96.7M opioid legal charge and $50.7M TRA expense, while FY2024's GAAP loss was itself depressed by those same items even as operating cash flow stayed positive at $295.1M; the recurring cash-based run-rate is better characterized by five consecutive years of positive operating cash flow ($65.1M-$345.6M) and FY2025 free cash flow of $269.9M than by either GAAP headline, and the reported ROE of 131.7% is a near-zero/negative-equity artifact (FY2025 stockholders' equity was a $70.8M deficiency) that is treated as non-meaningful. Valuation is the main offset: trailing P/E of 49.7x on depressed GAAP earnings, EV/EBITDA of 15.8x, EV/Sales of 3.31x and a free-cash-flow yield of only 0.54% are expensive for a generic-drug manufacturer, and both discounted-cash-flow models sit far below the quote ($9.63 levered and $13.68 unlevered versus $21.38), although those models are built on a trailing cash base that excludes any Kashiv contribution. The sell side remains constructive (consensus target $23.33; recent JP Morgan, Barclays, UBS, Leerink and Truist actions all Outperform or Buy), free float is 45% and the Amneal Group controls roughly 48% of voting power; several officers and directors sold shares in August 2026 with no offsetting open-market purchases. The industry-aware metric-grade cross-check landed in the lower-middle of its scale (valuation and intrinsic value weak, risk weak on leverage, profitability and growth solid) and rounded to the same middle-of-scale verdict reached independently; intrinsic value was the weakest category and provided a soft downward nudge, while the risk-imbalance override did not fire because risk was not the weakest category. Net: an improving operator with real leverage, cash-conversion and governance overhangs and a demanding multiple, which reads as a mixed and uncertain fundamental picture rather than a clean buy or a distress case.
Sentiment
fairSentiment is stable with no immediate catalysts, and media coverage reflects a balanced view.
Q3 2026 results (2026-11-03, announced) are the dominant driver — a revenue and adjusted-EPS beat with raised FY2026 revenue guidance that the tape clearly rewarded (multiple beat/raise items scored roughly +0.30 to +0.60, a 52-week high at $21.18, and a Leerink price-target raise to $25 from $23) — but the catalyst is seven days trailing and only partially priced, with a GAAP net loss, lowered operating-cash-flow guidance, a stale $522.69M shelf registration and August insider sales as offsets. The 14-day media polarity (≈ +0.22 across 11 scored items) is flat against the 80-day baseline (≈ +0.24 across 19 scored items), retail is indeterminate (Reddit 403 on both queries), and the Red-Flag Screen is clean with no severe or moderate flag fired.
Technical
fairThe stock is in a strong trend above key moving averages, but momentum indicators are neutral.
Trend: price 21.38 marks above SMA20 20.35 (+5.1%), SMA50 19.49 (+9.7%), SMA200 15.99 (+33.7%), EMA9 20.66, EMA21 20.38, WMA9 20.59, WMA21 20.57, DEMA14 20.84, TEMA14 20.80 and the 21.35 daily VWAP; the SMA20>SMA50>SMA200 stack is aligned upward and the 200-day has risen every session in the window. Momentum: RSI14 60.65 (up from 43.60 on 2026-11-05), Williams %R -11.28 (upper quartile but not yet vertical), MACD line 0.34 / signal 0.35 / histogram -0.01 — the line stays above zero while the histogram has improved four sessions running (-0.15, -0.15, -0.07, -0.01), so a bullish cross is imminent but unconfirmed. ADX14 17.95 is neutral-to-weak and falling from 22.28, confirming a consolidation tape rather than a trending thrust; read together with price above all MAs, this is a trend at rest, not a trend reversing. Volatility: ATR14 $0.84 = 3.93% of price, comfortably above the 1.0% compression floor and below the 9% high-volatility tier; StdDev20 0.82. Volume: avgDollarVolume20 $88.1M dwarfs the $5M floor, and the recent three regular-session dollar volumes (~$39.2M on 2026-11-06, ~$44.3M on 2026-11-09, ~$36.6M on 2026-11-10, averaging ~$40.0M) clear the $1.5M recent-liquidity floor by an order of magnitude — but the internal trend is negative, with the up-days of 2026-11-06/09/10 printing 4.73M / 2.63M / 2.25M shares against 7.23M and 4.95M on the 2026-11-04/05 down-days, a mild distribution/volume-divergence flag. Events: fmp_earnings_calendar (2026-10-11 to 2027-02-08), fmp_dividends_calendar and fmp_splits_calendar each returned zero records for AMRX (the company has never paid a common dividend), so there is no earnings blackout, no dividend blackout, and no qualifying event inside the 15-trading-day holding window through horizon_date 2026-12-02 returned by calc_trading_days_forward. Extended hours: the 2026-11-10 after-hours prints finished at 21.38, level with the regular-session close (closing auction 21.38), so no after-hours markup distorts the limit level. Structure: the M=2 regular-session window (atr14/close = 3.93% < 5%; no session range reaches 3xATR 2.52, so no catalyst-day anchor applies) spans 2026-11-09 (regular low 20.29) and 2026-11-10 (regular low 21.035); the sub-entry swingLow is 20.29, buffer max(0.03, 0.2x0.84) = 0.17, giving a structural stop of 20.12, which is widened to the Change-A pullback floor at 19.54 (entry - 1.0xATR) because the raw structural distance of 0.26 = 0.31xATR sits inside one session's noise. Plan: limit 20.38, stop 19.54, T1 22.06, T2 23.32, R/R 2.00. Rejected alternative: a buy-stop breakout above the settled 21.68 shelf (highs of 21.68 on 2026-10-28, 2026-10-30 and 2026-11-02; year high 21.681; the running 2026-11-10 high of 21.63 sits below it) would carry the same 20.12 structural stop for 1.58 of risk = 1.88xATR against T1 23.38, i.e. R/R 1.06, below the 1.5 screen, so no breakout entry qualifies. Both entry classes were evaluated; the countertrend-limit clauses do not fire (price 21.38 is above SMA50 19.49 with macdLine 0.34 positive; price is above a rising SMA200 15.99 with SMA50 above SMA200), so the pullback bid is trend-aligned.
In-depth analysis
Valuation
- The high P/E ratio suggests the stock is expensive relative to its earnings.
- The EV/EBITDA ratio indicates the stock is somewhat overvalued compared to peers.
- The EV/Sales ratio is moderate, suggesting balanced valuation relative to revenue.
- The PEG ratio is healthy, reflecting strong earnings growth relative to its price.
- The low free cash flow yield indicates limited cash return relative to the stock price.
Profitability
- The ROIC is solid, indicating efficient use of capital.
- The EBITDA margin is strong, indicating healthy operational profitability.
- The net margin is moderate, reflecting acceptable profitability.
- The gross margin is strong, showing good cost management.
- The high ROE is an artifact of near-zero equity and not meaningful.
Growth
- The revenue CAGR is moderate, reflecting steady growth.
- The EPS CAGR is strong, indicating robust earnings growth.
- The EBITDA CAGR is moderate, reflecting steady operational growth.
Risk
- The high net debt to EBITDA ratio indicates significant leverage risk.
- The current ratio is strong, indicating good short-term liquidity.
- The beta suggests moderate market volatility relative to the index.
- The Z-score indicates some financial risk but not immediate distress.
- The interest coverage ratio is moderate, indicating adequate ability to cover interest expenses.
Discounted Cash Flow
Callout
Both DCF models are well below the market price, indicating potential overvaluation based on current cash flow assumptions.
Trade plan
- Entry
- 20.38
- Protective stop
- 19.54
- Target 1
- 22.06
- Target 2
- 23.32
- Reward : risk
- 2.00 : 1
You’re looking at 2026-11-10 — more than 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.

